Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 300 | 4p15.32 | CD38 | CD38 molecule | 7 |
Mouse | 1 | 304 | 5 23.85 cM | Cd38 | CD38 antigen | |
Rat | 1 | 303 | 14q21 | Cd38 | CD38 molecule |
Previous and Unofficial Names |
ADP-ribosyl cyclase 1 |
Database Links | |
Alphafold | P28907 (Hs), Q4FJL8 (Mm), Q64244 (Rn) |
ChEMBL Target | CHEMBL4660 (Hs) |
Ensembl Gene | ENSG00000004468 (Hs), ENSMUSG00000029084 (Mm), ENSRNOG00000003069 (Rn) |
Entrez Gene | 952 (Hs), 12494 (Mm), 25668 (Rn) |
Human Protein Atlas | ENSG00000004468 (Hs) |
KEGG Gene | hsa:952 (Hs), mmu:12494 (Mm), rno:25668 (Rn) |
OMIM | 107270 (Hs) |
Pharos | P28907 (Hs) |
RefSeq Nucleotide | NM_001775 (Hs), NM_007646 (Mm), NM_013127 (Rn) |
RefSeq Protein | NP_001766 (Hs), NP_031672 (Mm), NP_037259 (Rn) |
SynPHARM | 82660 (in complex with isatuximab) |
UniProtKB | P28907 (Hs), Q4FJL8 (Mm), Q64244 (Rn) |
Wikipedia | CD38 (Hs) |
Selected 3D Structures | |||||||||||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific inhibitor tables |
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
CD38 is a type II transmembrane glycoprotein, that is widely expressed on immune cells and is involved in cell adhesion and signal transduction. Its extracellular domain acts as an ectoenzyme, catalyzing the conversion of nicotinamide adenine dinucleotide (NAD+) into nicotinamide, adenosine diphosphate-ribose (ADPR), and cyclic ADPR. Expression of CD38 is tightly regulated during B-cell development and maturation [6]. Since CD38 is expressed in a subset of haematological tumours, particularly in plasma cell tumours such as multiple myeloma (MM), anti-CD38 monoclonal antibodies have been developed with immuno-oncology potential as their main indication. Daratumumab (a MM therapeutic) was the first-in-class anti-CD38 antibody to reach the clinic. Additional investigational CD38-targeting antibodies include isatuximab (SAR650984, ImmunoGen) [3], MOR202 (MorphoSys) [1], AT13/5 (Tenovus Research) [5] and mezagitamab (Takeda) [10], which were all primarily developed for MM and other haematological cancers. However, anti-CD38 monoclonals may have applications in the treatment of diseases in addition to haematological malignancies, including solid tumours and antibody-mediated autoimmune diseases. |
Cell Type Associations | ||||
|
||||
|
||||
|
||||
|
||||
|
Immuno Process Associations | ||
|
||
|
||
|
||
|
1. Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia, 32 (2): 252-262. [PMID:29257139]
2. De Weers M, Graus Y, Oprins J, Parren P, Van De Winkel J, Van Vugt M. (2010) Antibodies Against Cd38 For Treatment Of Multiple Myeloma. Patent number: US7829673. Assignee: Genmab A/S. Priority date: 23/03/2005. Publication date: 09/11/2010.
3. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C et al.. (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res, 20 (17): 4574-83. [PMID:24987056]
4. Elias KA, Landes G, Singh S, Korver W, Drake AW, Haak-Frendscho M, Snell GP, Bhaskar V. (2012) Anti-cd38 antibodies. Patent number: WO2012092612A1. Assignee: Takeda Pharmaceutical Company Limited. Priority date: 30/12/2010. Publication date: 05/07/2012.
5. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol, 155 (2): 925-37. [PMID:7608568]
6. Hamblin TJ. (2003) CD38: what is it there for?. Blood, 102: 1939-1940. DOI: 10.1182/blood-2003-07-2332
7. Jackson DG, Bell JI. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol, 144 (7): 2811-5. [PMID:2319135]
8. Lagu B, Wu X, Kulkarni S, Paul R, Becherer JD, Olson L, Ravani S, Chatzianastasiou A, Papapetropoulos A, Andrzejewski S. (2022) Orally Bioavailable Enzymatic Inhibitor of CD38, MK-0159, Protects against Ischemia/Reperfusion Injury in the Murine Heart. J Med Chem, 65 (13): 9418-9446. [PMID:35762533]
9. Park PU, Bartle L, Skaletskaya A, Golmakher V, Tavares D, Deckert J, Milol V, Blanc V. (2011) Novel anti-cd38 antibodies for the treatment of cancer. Patent number: US20110262454 A1. Assignee: Sanofi-Aventis. Priority date: 20/08/2015. Publication date: 27/10/2011.
10. Roepcke S, Plock N, Yuan J, Fedyk ER, Lahu G, Zhao L, Smithson G. (2018) Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect, 6 (3): e00402. [PMID:29864242]
Abscisic acid receptor complex: CD38. Last modified on 08/08/2022. Accessed on 09/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2766.